|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2002-4-2
|
|
pubmed:abstractText |
Augmentation strategies in schizophrenia treatment remain an important issue because despite the introduction of several new antipsychotics, many patients remain treatment resistant. The aim of this study was to undertake a systematic review and meta-analysis of the safety and efficacy of one frequently used adjunctive compound: carbamazepine.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0160-6689
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
63
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
218-24
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11926721-Anticonvulsants,
pubmed-meshheading:11926721-Antimanic Agents,
pubmed-meshheading:11926721-Antipsychotic Agents,
pubmed-meshheading:11926721-Carbamazepine,
pubmed-meshheading:11926721-Cross-Over Studies,
pubmed-meshheading:11926721-Drug Therapy, Combination,
pubmed-meshheading:11926721-Evidence-Based Medicine,
pubmed-meshheading:11926721-Humans,
pubmed-meshheading:11926721-Outcome Assessment (Health Care),
pubmed-meshheading:11926721-Randomized Controlled Trials as Topic,
pubmed-meshheading:11926721-Schizophrenia
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Carbamazepine augmentation for schizophrenia: how good is the evidence?
|
|
pubmed:affiliation |
Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universität München, Germany. Stefan.Leucht@Lrz.tu-muenchen.de
|
|
pubmed:publicationType |
Journal Article,
Review,
Meta-Analysis
|
